Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela® to Asian patients

SINGAPORE , July 21, 2026 /PRNewswire/ -- Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela ® (trilaciclib) across its Asia-Pacific markets.

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells). For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes [1] . Cosela ® is a first-in-class prophylactic therapy [2] FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.

Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela ® in Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.